PRLD earnings analysis
What we found in PRLD's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted portion of Prelude Therapeutics’ June 30, 2026 Form 10-Q contains no income statement, balance sheet, cash-flow, segment, or quantitative guidance data, so period-over-period financial trends cannot be assessed from the available filing text. Management reported effective disclosure controls as of June 30, 2026 and no material internal-control changes during the quarter. The filing does not update the risk-factor framework from the 2025 Form 10-K filed March 10, 2026, while reiterating ongoing litigation and clinical-stage investment risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure Controls Remain Effective
- Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2026.
- No Material Control Changes
- Management reported no changes in internal control over financial reporting during the fiscal quarter ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, controls.
- No New Unregistered Securities
- The company reported that it did not issue or sell any previously undisclosed unregistered securities during the three months ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Core Clinical-Stage Risks Remain
- The filing states that investing in the common stock involves a high degree of risk and directs investors to the risk factors in the 2025 Annual Report filed March 10, 2026; no new or amended risk factors are identified in this 10-Q.
- Potential IP and Litigation Exposure
- Although management says it is not presently party to litigation expected to have a material adverse effect, the company notes that litigation can still create defense and settlement costs, management-resource diversion, negative publicity, and reputational harm.
- Limited Market-Risk Disclosure
- As a smaller reporting company, Prelude is not required to provide quantitative and qualitative market-risk disclosures for the period ending June 30, 2026, limiting visibility into market-risk exposures.
What they said about what is next.
The extracted 10-Q text does not provide quantitative revenue or EPS guidance, nor a new qualitative outlook. Numeric outlook may be deferred to the earnings press release or call.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 12, 2026
- Prelude Therapeutics reported revenue of $4.58 million for Q1 2026, driven by an Exclusive Option Agreement with Incyte. The company's diluted EPS improved significantly from -$0.42 in Q1 2025 to -$0.13, reflecting a…
- 10-K · March 10, 2026
- Prelude positions itself as a precision-oncology biotech focused on novel modalities (kinase inhibitors, targeted protein degraders, precision ADCs) and emphasizes internal discovery + selective partnering to advance…
- 10-Q · November 12, 2025
- Prelude reported Q3 2025 revenue of $6.5M (up from $3.0M in Q3 2024) and a narrower net loss of $19.7M (EPS -$0.26) versus a net loss of $32.3M (EPS -$0.43) in Q3 2024. Operating expenses declined as R&D fell to…
- 10-Q · May 6, 2025
- Prelude reported a net loss of $32,085,000 (GAAP) for the quarter ended March 31, 2025, or $(0.42) per share, essentially unchanged versus $(0.42) in Q1 2024. Cash, cash equivalents, restricted cash and marketable…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PRLD makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever